Zoetis Inc. (ZTS)
Health Care3 articles
Market Mood
Zoetis (ZTS) Director Michael McCallister Buys $233,273 in Shares
Michael McCallister, a director at Zoetis (ZTS), purchased shares totaling $233,273. This stock buy may signal McCallister's confidence in the company’s future prospects. Such insider buying can influence market perceptions and potentially affect stock prices as investors interpret it as positive sentiment regarding the company's trajectory. Monitoring these insider trades can provide insights into the firm's growth potential and market strategy.
Read More
Zoetis (ZTS) Releases DEF 14A Filing for April 30 Meeting
Zoetis Inc (ZTS) filed its DEF 14A with the SEC for the upcoming shareholder meeting on April 30. This filing includes details on executive compensation and proposed changes to governance. Such disclosures are vital for investors assessing company management and expected performance. The filing may influence shareholder voting on key issues affecting the business.
Read More
Zoetis (ZTS) Q3 2024 Revenue Grows 14% Operationally
In Q3 2024, Zoetis (ZTS) reported a 14% operational revenue growth, driven by a 15% increase in the U.S. and a 13% increase internationally. Adjusted net income saw a 15% operational rise, with key franchises, including the companion animal portfolio, also growing by 15%. The osteoarthritis pain franchise, consisting of Librela and Solensia, delivered a significant 97% operational revenue increase globally. This consistent growth reflects demand for their diverse and science-driven portfolio, positioned to address customer needs effectively.
Read More